Ratings by RBC Capital (Trung Huynh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/10/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2026 | Pfizer | PFE | Upgrade | Sector Perform (Underperform) |
25.62 (25.05) |
-2.22% | Details | |
| 5/4/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 4/20/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 3/16/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Abbvie | ABBV | New Coverage | Outperform (N/A) |
229.48 (254.49) |
10.9% | Details | |
| 2/24/2026 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
1058.56 (1179.11) |
11.39% | Details | |
| 2/24/2026 | Pfizer | PFE | New Coverage | Underperform (N/A) |
27.06 (25.62) |
-5.32% | Details | |
| 2/24/2026 | Merck | MRK | New Coverage | Outperform (N/A) |
123.82 (127.50) |
2.97% | Details | |
| 2/24/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Sector Perform (N/A) |
61.25 (60.74) |
-0.83% | Details |
